They appear to be placing a number of publicity shots for maybe revenue raising, not so much because it is "so" effective.
Current drugs for secondary progressive MS only treat the symptoms of the disease. But MIS-416 is the first aimed at modulating the part of the immune system which is attacking itself.
"We've got an immune system that's out of control in these patients and we're ramping up that part of the immune system that's responsible for re-gaining control," says Innate Immunotherapeutic chief executive Simon Wilkinson.
To give thins perspective, I always compare statements against what was coming out about Aimspro, which also never really eventuated as hoped and believed by many.allynz wrote:http://tvnz.co.nz/national-news/christchurch-trial-paves-way-new-ms-treatment-5297796
It seems there are several people taking the drug after the trial because they don't want to go back to life before the drug. It is interesting to me because very few treatments are for ppms or spms but this one is.
But that is interesting to me.allynz wrote:The next phase of the trial is in Australia.
Users browsing this forum: vilnietis